DNA Damage Repair Protein DNMT3L: Potential Drug Target and Cancer Diagnosis

Target Name: DNMT3L

NCBI ID: G29947

DNMT3L

DNA Damage Repair Protein DNMT3L: Potential Drug Target and Cancer Diagnosis

DNA damage repair (DNA damage repair, DNA damage repair, DNA repair) is a crucial process in maintaining the integrity of DNA in living organisms. DNA damage can result from various factors, including exposure to mutagenic agents, radiation, and errors during DNA replication. When DNA is damaged, the cell must repair the damage before any further damage can occur. If the repair process fails, the cell may become cancerous.

DNMT3L (DNMT3L variant 1) is a protein that is involved in the DNA damage repair pathway. It is a key player in the repair of DNA double-strand breaks, which are the most common type of DNA damage.

In recent years, research has identified DNMT3L as a potential drug target for various diseases, including cancer. The reason for this is that DNMT3L has been shown to promote the growth and survival of cancer cells, and it has also been shown to contribute to the development of certain types of cancer.

One of the reasons for the potential of DNMT3L as a drug target is its ability to induce cell death in cancer cells. This is achieved by activating programmed cell death (apoptosis), which is a natural mechanism that helps the body eliminate damaged or dysfunctional cells.

In addition to its ability to induce apoptosis, DNMT3L has also been shown to inhibit the growth and survival of cancer cells. This is achieved by inhibiting the S-phase checkpoint, a critical step in the cell cycle that allows cells to grow and divide.

DNMT3L has also been shown to promote the formation of immune cells, which are important for fighting off cancer. This is achieved by promoting the production of T cells, which are a crucial part of the immune system.

In addition to its potential as a drug target, DNMT3L is also of interest as a biomarker for cancer. This is because its levels have been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that DNMT3L may be a useful diagnostic tool for cancer.

DNMT3L has also been shown to be involved in the regulation of the cell cycle. This is achieved by regulating the activity of the checkpoint protein, which is responsible for ensuring that the cell cycle proceeds in a orderly and accurate manner.

In conclusion, DNMT3L is a protein that is involved in the DNA damage repair pathway. It has been shown to promote the growth and survival of cancer cells, and it has also been shown to contribute to the development of certain types of cancer. In addition to its potential as a drug target and biomarker, DNMT3L is also of interest as a target for cancer diagnosis. Further research is needed to fully understand the role of DNMT3L in the development and progression of cancer.

Protein Name: DNA Methyltransferase 3 Like

Functions: Catalytically inactive regulatory factor of DNA methyltransferases that can either promote or inhibit DNA methylation depending on the context (By similarity). Essential for the function of DNMT3A and DNMT3B: activates DNMT3A and DNMT3B by binding to their catalytic domain (PubMed:17687327). Acts by accelerating the binding of DNA and S-adenosyl-L-methionine (AdoMet) to the methyltransferases and dissociates from the complex after DNA binding to the methyltransferases (PubMed:17687327). Recognizes unmethylated histone H3 lysine 4 (H3K4me0) and induces de novo DNA methylation by recruitment or activation of DNMT3 (PubMed:17687327). Plays a key role in embryonic stem cells and germ cells (By similarity). In germ cells, required for the methylation of imprinted loci together with DNMT3A (By similarity). In male germ cells, specifically required to methylate retrotransposons, preventing their mobilization (By similarity). Plays a key role in embryonic stem cells (ESCs) by acting both as an positive and negative regulator of DNA methylation (By similarity). While it promotes DNA methylation of housekeeping genes together with DNMT3A and DNMT3B, it also acts as an inhibitor of DNA methylation at the promoter of bivalent genes (By similarity). Interacts with the EZH2 component of the PRC2/EED-EZH2 complex, preventing interaction of DNMT3A and DNMT3B with the PRC2/EED-EZH2 complex, leading to maintain low methylation levels at the promoters of bivalent genes (By similarity). Promotes differentiation of ESCs into primordial germ cells by inhibiting DNA methylation at the promoter of RHOX5, thereby activating its expression (By similarity)

The "DNMT3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNMT3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets